VolitionRx Limited (VNRX) Fair Value & Analysis
Healthcare · US · Market cap $5.7M · ISIN US9286612067
What is VolitionRx Limited really worth?
VolitionRx Limited
VNRX · US
Below-average quality, trading 61% below our fair value of $0.8915.
As of Aug 23, 2026, the fair value of VolitionRx Limited is $0.8915 per share against a price of $0.3496, so the fair value sits 155% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Aug 23, 2026
From 2 valuation models · updated 14 days ago
Share price −56.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case ($0.4666). The market is more pessimistic than our downside scenario.
- The model range is unusually wide ($0.4666 to $1.30). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 23, 2026.
How to read this chart
60‑month range $0.3392 – $82.60 · fair‑value band $0.4666 – $1.30 · the $0.3496 price screens below the $0.8915 fair value. Dashed = 300-day average. As of Aug 23, 2026.
Analysis
VolitionRx Limited (VNRX) currently trades at $0.3496, while our model-based Fair Value estimate is $0.8915, implying the stock looks roughly 60.8% undervalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 3 models at a data quality of 81/100, which puts the evidence level at low.
Trailing-twelve-month revenue stands at $2.5M. Revenue grew 299.8% year over year. Net debt stands at $10.3M. Fundamentals as of Aug 23, 2026
Our scenario range runs from $0.4666 (bear case) to $1.30 (bull case); at $0.3496, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at 155%, VNRX screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 2 models by family
Notify me when VNRX reaches fair value
Put VNRX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 28 · Market factors (momentum, volatility) 7
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
Full company description
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
VolitionRx Limited reported revenue of $1.7M in FY2025 versus $90.0K in FY2021, a compound +109.3%/yr. Reported net income was −$23.4M in FY2025.
Watch VNRX: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare VolitionRx Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is VolitionRx Limited (VNRX) overvalued or undervalued?
What is the fair value of VNRX?
What is the quality score of VNRX?
What is the price target for VolitionRx Limited (VNRX)?
What is the VolitionRx Limited stock forecast for 2026?
What is the revenue of VolitionRx Limited (VNRX)?
What is the net profit margin of VNRX?
Does VolitionRx Limited pay a dividend?
Watch VolitionRx Limited in the live analysis
One click puts VolitionRx Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.